Xeris Pharmaceuticals Announces Appointment of Paul R.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
46
Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO

Austin, Texas, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of injectable drugs, announced that Mr. Paul R. Edick has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective January 9, 2017. Mr. Edick is a highly accomplished pharmaceutical industry executive who most recently served as CEO of Durata Therapeutics, which he and his team built, took public, and sold to Actavis PLC, now known as Allergan PLC. 

"Paul is a leader whose record shows a relentless focus on leadership, execution and high performance, and we are fortunate to have an executive of his caliber to take Xeris forward. Paul’s decades of experience leading companies in the pharmaceutical industry, his vision, and his leadership make him uniquely qualified to lead Xeris at this moment of great opportunity for the company” said Robert C. Faulkner, Member of Xeris’ Board of Directors.  “With the support of our talented team, we are confident that Paul will create compelling value and opportunity for employees and shareholders.”  He succeeds Mr. Douglas Baum, who is stepping down from his role as President and Chief Executive Officer and will serve as a consultant to the Company.

Mr. Faulkner continued, "We are grateful for Doug’s dedication to Xeris since soon after its founding and look forward to his continued support to ensure a smooth transition through his role as a consultant." Mr. Baum added, “Xeris’ significant opportunities in the near term merit a proven hand at building out companies for commercialization.  As a significant shareholder and a believer in the technology, I am gratified to hand this promising company to an executive with such a track record of success.”

Xeris’ lead drug product candidate is G-Pen®, a novel glucagon formulation based on the Company’s proprietary formulation technology Xerisol®, that is delivered through a pre-filled injector to treat hypoglycemia in diabetics.  G-Pen is expected to be stable for long periods at room temperature and easy for patients and caregivers to use. 

About Paul R. Edick

From July 2010 to November 2014, Mr. Edick served as Chief Executive Officer of Durata Therapeutics Inc., a biopharmaceutical company addressing the growing need for new therapeutics to treat infectious diseases, which was acquired by Actavis plc. in 2014.  During Mr. Edick’s tenure at Durata, he  assembled a premier team of pharmaceutical and biopharmaceutical executives, guided the company through FDA approval, took the company public, oversaw the launch of the lead product and sold the company to Actavis plc, now known as Allergan plc. 

Prior to his tenure at Durata, Mr. Edick was Chairman and Chief Executive Officer of Ganic Pharmaceuticals Inc. from March 2008 to June 2010. Ganic was a vehicle funded by Warburg Pincus to find acquisition opportunities in specialty pharmaceuticals. 

From April 2002 to February 2008, Mr. Edick was President, and then Chief Executive Officer, of Medpointe Healthcare Inc., a private equity sponsored, acquisition focused,  specialty pharmaceutical company. As CEO, he assembled a premier team of pharmaceutical executives, refocused the strategy, lead the development of a pipeline of products, the restructuring of company debt, built significant value and negotiated sale of the company to Meda AB of Sweden in 2007.  Previous experience includes domestic and international roles of increasing responsibility at Pharmacia Corporation, Searle Pharmaceutical Inc., Baxter Healthcare Corporation, and Ortho Pharmaceutical Corp.

Mr. Edick also serves on the Boards of Directors for  Iterum Therapeutics Limited, NewLink Genetics Corporation, PDL BioPharma, Inc., Neos Therapeutics and Sucampo Pharmaceuticals, Inc.  He earned a bachelor’s degree from Hamilton College. 

About Xeris Pharmaceuticals, Inc.

Xeris is an Austin, Texas-based, specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes. The company's proprietary XeriSol™ and XeriJect™ formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-inject formulations of peptides, proteins, antibodies and small molecules using auto-injectors, multi-dose pens and pumps. Xeris' proprietary formulation platforms have the potential to offer distinct advantages over existing products and formulations including: up to 1000-fold lower injection volumes, long term room-temperature stability, elimination of reconstitution and refrigeration, all of which can lead to products that are easier to use by patients, caregivers, health practitioners, and can reduce costs for payers and the healthcare system. For more information please visit the Xeris website at: www.xerispharma.com.

Xeris Media Contact Brad Huckabee Xeris Pharmaceuticals, Inc. www.xerispharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 16

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 150

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 132

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 127

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 91

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 28

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 213

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 144

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading

Top 5 Most Recently Viewed Articles

Soka Gakkai International's Commitment to Peace and Dialogue

Updated Category News Views 482

Soka Gakkai International Empowers Dialogue at Peace Forum Recently, Soka Gakkai International (SGI) announced its participation in a significant event dedicated to peace and dialogue. This forum will take place following a prestigious Nobel Peace Prize ceremony where the Association of Hibakusha will receive accolades for their enduring advocacy for world peace. A Forum...

Continue Reading
Harnessing AI for Effortless Image and Video Creation with Sisi

Updated Category News Views 369

Revolutionizing Visual Content Creation with AI In an age where digital visuals play a crucial role in communication, Fotor stands out as a pioneer in enhancing creativity with technological prowess. The company has recently introduced the Fotor AI Agent, affectionately known as Sisi, an innovative AI-powered assistant geared to simplify the process of creating images and...

Continue Reading
China Hour Expands Chinese Media Footprint in Africa

Updated Category News Views 51

An Ambitious Cross-Continental Media Play The airwaves are getting a new twist. This time, it's a blend of cultures, as China Hour makes an entrance in South Africa. That's right, folks—Jiangsu Broadcasting Corporation (JSBC) has set up camp alongside the South African Broadcasting Corporation (SABC), pushing a big media wave across the continent. If you've been...

Continue Reading
BlockFills Enhances Liquidity for Institutional Traders in Crypto

Updated Category News Views 209

BlockFills Partners with CoinDesk Indices for Enhanced Market Liquidity BlockFills, a prominent player in the digital assets sector, is making strides to improve liquidity in the cryptocurrency market. Its recent collaboration with CoinDesk Indices aims to establish an institutional-grade options market, particularly targeting the CoinDesk 20 Index. This initiative is...

Continue Reading
Understanding the Recent Options Trends with Airbnb (NASDAQ: ABNB)

Updated Category News Views 101

Airbnb's Options Activity Explained Investors are eyeing Airbnb (NASDAQ: ABNB) with a fair amount of skepticism lately. Notably, there has been a noteworthy increase in bearish options activity, a trend that could indicate potential shifts in market dynamics that traders should not take lightly. Our observations reveal significant insights into how savvy players are...

Continue Reading